Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

Company Overview

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $55.47 to $58.16
• 50-Day Range: $47.73 to $67.33
• 52-Week Range: $35.17 to $68.58
• Volume: 1.52 million shs
• Average Volume: 548,620 shs
• Market Capitalization: $3.45 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $65.80
• Consensus Rating: Moderate Buy

Rhythm Pharmaceuticals Stock Analysis - MarketRank™

Rhythm Pharmaceuticals scored higher than 82% of companies evaluated by MarketBeat, and ranked 199th out of 947 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Rhythm Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($4.34) to ($2.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rhythm Pharmaceuticals is -12.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rhythm Pharmaceuticals is -12.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rhythm Pharmaceuticals has a P/B Ratio of 19.55. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.36% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Rhythm Pharmaceuticals has recently decreased by 5.07%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rhythm Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rhythm Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.3 / 5
• Environmental Score: -1.80

Percentage of Shares Shorted

10.36% of the outstanding shares of Rhythm Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 12.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Rhythm Pharmaceuticals has recently decreased by 5.07%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.12

News Sentiment

Rhythm Pharmaceuticals has a news sentiment score of 1.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Rhythm Pharmaceuticals this week, compared to 7 articles on an average week.

Search Interest

2 people have searched for RYTM on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

4 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,622,000.00 in company stock.

Percentage Held by Insiders

Only 5.60% of the stock of Rhythm Pharmaceuticals is held by insiders.

RYTM Stock Analysis - Frequently Asked Questions

How have RYTM shares performed this year?

Rhythm Pharmaceuticals' stock was trading at $45.97 at the beginning of 2024. Since then, RYTM shares have increased by 22.1% and is now trading at $56.12.
View the best growth stocks for 2024 here.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) posted its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.80) by $0.07. The business's quarterly revenue was up 47.6% on a year-over-year basis.

When did Rhythm Pharmaceuticals IPO?

Rhythm Pharmaceuticals (RYTM) raised $100 million in an initial public offering (IPO) on Thursday, October 5th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen served as the underwriters for the IPO and Needham was co-manager.

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' top institutional shareholders include Primecap Management Co. CA (11.81%), Frazier Life Sciences Management L.P. (3.93%), State Street Corp (3.24%) and Geode Capital Management LLC (2.04%). Insiders that own company stock include David P Meeker, Hunter C Smith, Yann Mazabraud, Pamela J Cramer, William T Roberts, Jennifer Chien, Jennifer L Good, Lynn A Tetrault, Jennifer Kayden Lee, Christopher Paul German and Joseph Shulman.
View institutional ownership trends.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Rhythm Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Netflix (NFLX), Tesla (TSLA) and Palo Alto Networks (PANW).

Company Calendar

• Last Earnings: 11/05/2024
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RYTM
• CUSIP: N/A
• CIK: 1649904
• Web: www.rhythmtx.com
• Phone: (857) 264-4280
• Fax: 857-264-4299
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $65.80
• High Stock Price Target: $80.00
• Low Stock Price Target: $52.00
• Potential Upside/Downside: +17.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($4.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-184,680,000.00
• Net Margins: -230.07%
• Pretax Margin: -229.52%
• Return on Equity: -367.36%
• Return on Assets: -77.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.49
• Quick Ratio: 3.34

Sales & Book Value

• Annual Sales: $112.53 million
• Price / Sales: 30.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.87 per share
• Price / Book: 19.55

Miscellaneous

• Outstanding Shares: 61,457,000
• Free Float: 58,015,000
• Market Cap: $3.45 billion
• Optionable: Optionable
• Beta: 2.14